A post-hoc analysis [52] of SAVOR-TIMI 53 trial found that hypoglycemia rates (any or major) were increased with saxagliptin in patients taking sulfonylureas, not in those taking insulin. The gene discussed is INS; the disease is Hypoglycemia.